Aug 17 |
BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon
|
Aug 3 |
BridgeBio Pharma Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
Aug 1 |
BridgeBio Pharma GAAP EPS of -$0.59
|
Aug 1 |
BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates
|
Aug 1 |
BridgeBio Pharma: Q2 Earnings Snapshot
|
Aug 1 |
BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update
|
Jul 23 |
BridgeBio Pharma appoints Thomas Trimarchi COO
|
Jul 23 |
BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
|
Jun 27 |
BridgeBio Pharma, Inc. (BBIO): Is This Healthcare Stock a Strong Buy?
|
Jun 18 |
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
|